Oral nitroglycerin paste did not lower pulmonary capillary pressure during treadmill exercise.
We hypothesised that 22.5 mg of oral nitroglycerin would cause pulmonary vasodilation and therefore decrease pulmonary capillary pressure in horses during strenuous exercise. Six horses were assigned to exercise twice, once with no medication (control) and once with nitroglycerin (22.5 mg orally) in random order. Horses were exercised for 3 min each at 75, 90 and 100% of maximal heart rate (HRmax) with a 2 min period of walking between each period of exertion. Pulmonary artery and oesophageal pressures were recorded continuously. Subsequent analysis was carried out on the pulmonary arterial pressure signal with the oesophageal pressure subtracted, hence pulmonary vascular pressures reported in this paper approximate transmural pressures. Pulmonary arterial pressure, pulmonary arterial wedge pressure, pulmonary capillary pressure, heart rate and arterial blood gas tensions were determined for each level of exercise. Pulmonary arterial wedge and pulmonary capillary pressures were determined from the pulmonary artery waveform after dynamic occlusion of a branch of the pulmonary artery. The resulting decay in pulmonary artery pressure was submitted to an exponential curve fitting and the amplitude at the moment of occlusion on this curve was recorded as pulmonary capillary pressure. The effects of nitroglycerin on the various parameters were evaluated using a 3-way ANOVA blocked on horse treatment, and exercise intensity, followed by Tukey's multiple comparison procedure. Resting pulmonary artery pressure decreased from mean +/- s.e. 34.0 +/- 5.5 mmHg to 24.0 +/- 3.9 mmHg 5 min after administration of nitroglycerin (P < 0.05) but there were no significant effects on pulmonary capillary or wedge pressures. Nitroglycerin at this dose resulted in no significant differences in pulmonary artery, pulmonary capillary, and pulmonary wedge pressure, heart rate, arterial oxygen tension or arterial carbon dioxide tension at 75, 90 and 100% of HRmax. This dose of nitroglycerin does not appear significantly to protect the pulmonary vascular bed from exercise-induced hypertension. These data do not support the use of this dose of oral nitroglycerin in the prevention of EIPH.
Hackett
R P
RP
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA.
Ducharme
N G
NG
Gleed
R D
RD
Erb
H N
HN
Mitchell
L M
LM
Soderholm
L V
LV
D000284:Administration, Oral; D000818:Animals; D005080:Exercise Test / Q000662:veterinary; D005260:Female; D006470:Hemorrhage / Q000662:veterinary; D006734:Horse Diseases / Q000517:prevention & control; D006736:Horses / Q000502:physiology*; D008297:Male; D005996:Nitroglycerin / Q000008:administration & dosage / Q000494:pharmacology*; D010805:Physical Conditioning, Animal / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects*
D005996:Nitroglycerin